Results 101 to 110 of about 56,538 (251)
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse +3 more
wiley +1 more source
Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis
Fingolimod is an oral sphingosine-1-phosphate (S1P) receptor modulator and the first oral therapy for relapsing-remitting multiple sclerosis. Its use has been complicated by a low rate of cystoid macular edema usually in the first 3 months after ...
Heather Gwen Mack +2 more
doaj +1 more source
A Case of Multiple Sclerosis Presenting as Eight and Half Syndrome. [PDF]
Multiple sclerosis (MS) is a chronic disease characterized by inflammation, demyelination, gliosis (scarring), and neuronal loss; the course can be relapsing-remitting or progressive.
Kaushik, M +4 more
core
Epilepsy syndromes classification
Abstract Epilepsy syndromes are distinct electroclinical entities which have been recently defined by the International League Against Epilepsy Nosology and Definitions Task Force. Each syndrome is associated with “a characteristic cluster of clinical and EEG features, often supported by specific etiologic findings”.
Elaine C. Wirrell +4 more
wiley +1 more source
Group sequential designs for negative binomial outcomes
Count data and recurrent events in clinical trials, such as the number of lesions in magnetic resonance imaging in multiple sclerosis, the number of relapses in multiple sclerosis, the number of hospitalizations in heart failure, and the number of ...
Friede, Tim +3 more
core +1 more source
The multiple hit model of infantile and epileptic spasms: The 2025 update
Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou +6 more
wiley +1 more source
Diagnosis and Management of Progressive Multiple Sclerosis
Multiple sclerosis is a chronic autoimmune disease of the central nervous system that results in varying degrees of disability. Progressive multiple sclerosis, characterized by a steady increase in neurological disability independently of relapses, can ...
Gabrielle Macaron, Daniel Ontaneda
doaj +1 more source
Personalized Treatment of Patients With Multiple Sclerosis: A Case Report and Literature Review
ABSTRACT Managing multiple sclerosis (MS) with a highly active disease course presents significant challenges, particularly regarding the timing of therapeutic escalation and the preservation of brain volume. We present a personalized management strategy for a 36‐year‐old male with relapsing‐remitting MS (RRMS) who experienced initial misdiagnosis ...
Fengjun Wang +3 more
wiley +1 more source
Matrix Metalloproteinase-9 and Inflammation in Different Types of Multiple Sclerosis [PDF]
Different clinical courses of multiple sclerosis, heterogeneity of its clinical implications, different effect of immunomodulatory therapy for the same clinical forms implies various pathogenetic mechanisms of central nervous system damage at this ...
Chernenko, M. (Maksym) +4 more
core +2 more sources
ABSTRACT Aims To explore the boundary of clinical use of sacral nerve stimulation (SNS) in neurogenic lower urinary tract dysfunction (NLUTD), identifying barriers to approval and early‐impact research questions. Methods This review is derived from a proposal discussion at the International Consultation on Incontinence‐Research Society in Bristol in ...
Marcus J. Drake +6 more
wiley +1 more source

